Roy’s expertise goes beyond his financial acumen,” said BJ Hardman, Chairman and CEO of Sanarus Technologies. “He’s a strategic thinker whose leadership and experience will help drive continued growth.”
Pleasanton, CA (PRWEB) January 11, 2016
Sanarus Technologies, a leading developer of minimally invasive medical devices for treating breast disease, today announced the appointment of Roy Little as chief financial officer. Mr. Little is a senior executive with more than forty years experience providing financial leadership and driving growth for established and startup organizations.
“Roy’s expertise goes beyond his financial acumen,” said BJ Hardman, Chairman and CEO of Sanarus Technologies. “He’s a strategic thinker whose leadership and experience will help drive continued growth.”
Mr. Little began his career at Cigna Corporation in Philadelphia, a global health insurance service company. Most recently, he was president and CEO of Insurance Educational Association (IEA), where he oversaw strategy, finance and business operations, successfully leading the company through the 2008-2011 economic downturn.
“It’s an exciting time to join the Sanarus team,” said Mr. Little. “The cryoablation market is poised for continued momentum and I’m looking forward to maximizing the potential for growth. We’re on track to outpace the industry by continuing to develop innovative, minimally invasive treatment solutions that elevate the standard of care.”
Mr. Little has held various executive and board positions with Argonaut Group, Pinkerton’s, Fireman’s Fund Insurance and ePolicy Solutions. He earned a bachelor’s degree from Cornell University and a master of business administration from Southern Illinois University.
Sanarus Technologies revolutionized the treatment of early stage breast disease and fibroadenomas with the development of the Visica 2™ Treatment System. The patented, FDA-cleared system uses extreme cold (cryo) to destroy tissue (ablation). The Visica 2 Treatment System kills the tumor by freezing it with liquid nitrogen and damaging the adjacent blood supply that fuels tumor growth.
Cryoablation offers benefits over surgery because the procedure is done under local anesthesia, no breast tissue is removed and the shape of the breast is maintained. Breast surgeons and interventional radiologists nationwide are using this advanced technology for the treatment of breast tumors as an alternative to surgical lumpectomy.
About Sanarus Technologies
In 2001, the Visica®Treatment System was the first system available for cryoablation of fibroadenomas. Since then, our systems have been used to successfully treat thousands of patients. The System is FDA-cleared for the ablation of cancerous or malignant tissue and benign tumors. Since 2007, the Visica 2 Treatment System has been used to treat cancer in hundreds of cryoablation-assisted surgeries and dozens of cryoablation-only procedures in clinical trials. At Sanarus, we pride ourselves in developing innovative solutions for the nonsurgical treatment of breast tumors. We are a woman-owned business, headquartered in Pleasanton, CA and all of our products are manufactured in the USA. Find out more at http://www.sanarus.com.